The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent

Toxicon

Volumn 59, Issue 4, 2012, Pages 464-471

  Furman, Brian L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Exendin 4; GLP 1; Insulin secretion

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 3; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; METFORMIN; PEPTIDE; SULFONYLUREA; UNCLASSIFIED DRUG; VENOM;

ACUTE PANCREATITIS; AMINO ACID SEQUENCE; ANTIDIABETIC ACTIVITY; CELL PROLIFERATION; CELL SURVIVAL; CONTINUOUS INFUSION; DECREASED APPETITE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG HALF LIFE; DRUG SAFETY; GLUCAGON RELEASE; HELODERMA SUSPECTUM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIZARD; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; LIZARDS; MOLECULAR SEQUENCE DATA; PEPTIDES; VENOMS;

HELODERMA SUSPECTUM; HELODERMATIDAE;

EID: 84857046993     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.12.016     Document Type: Review

References (107)

1. Alarcon C., Wicksteed B., Rhodes C.J. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006, 49:2920-2929.
2. Anderson S.L., Trujillo J.M. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann. Pharmacother. 2010, 44:904-909.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
4. Bayliss W.M., Starling E.H. Mechanism of pancreatic secretion. J. Physiol. (Lond) 1902, 28:235-334.
5. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve. Clin. J. Med. 2009, 76(Suppl. 5):S4-S11.
6. Bunck M.C., Cornér A., Eliasson B., Heine R.J., Shaginian R.M., Wu Y., Yan P., Smith U., Yki-Järvinen H., Diamant M., Taskinen M.R. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010, 212:223-229.
7. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Exenatide-113 clinical study group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
8. Buse J.B., Drucker D.J., Taylor K.L., Kim T., Walsh B., Hu H., Wilhelm K., Trautmann M., Shen L.Z., Porter L.E. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33:1255-1261. DURATION-1 Study Group.
9. Buteau J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42:856-864.
10. Chen T., Kwok H., Ivanyi C., Shaw C. Isolation and cloning of exendin precursor cDNAs from single samples of venom from the Mexican beaded lizard (Heloderma horridum) and the Gila monster (Heloderma suspectum). Toxicon 2006, 47:288-295.
11. Chen J., Yu L., Wang L., Fang X., Li L., Li W. Stability of synthetic exendin-4 in human plasma in vitro. Protein Pept. Lett. 2007, 14:19-25.
12. Chia C.W., Carlson O.D., Kim W., Shin Y.K., Charles C.P., Kim H.S., Melvin D.L., Egan J.M. Exogenous glucose-dependent insulinotropic polypeptide worsens post-prandial hyperglycemia in type 2 diabetes. Diabetes 2009, Mar 10. (Epub ahead of print).
13. Creutzfeldt W. The incretin concept today. Diabetologia 1979, 16:75-85.
14. Cunha D.A., Ladrière L., Ortis F., Igoillo-Esteve M., Gurzov E.N., Lupi R., Marchetti P., Eizirik D.L., Cnop M. Glucagon-like peptide-1 agonists protect pancreatic β-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009, 58:2851-2862.
15. D'Alessio D.A., Vogel R., Prigeon R., Laschansky E., Koerker D., Eng J., Ensinck J.W. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 1996, 97:133-138.
16. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
17. Denker P.S., Dimarco P.E. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006, 29:471.
18. Doyle M.E., Theodorakis M.J., Holloway H.W., Bernier M., Greig N.H., Egan J.M. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul. Pept. 2003, 114:153-158.
19. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E155-E161.
20. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 2002, 87:1282-1290.
21. Egan J.M., Meneilly G.S., Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1072-E1079.
22. Ellero C., Han J., Bhavsar S., Cirincione B.B., Deyoung M.B., Gray A.L., Yushmanova I., Anderson P.W. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. Diabet. Med. 2010, 27:1168-1173.
23. Elrick H., Stimmler L., Hlad C.J., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
24. Eng J., Andrews P.C., Kleinman W.A., Singh L., Raufman J.P. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J. Biol. Chem. 1990, 265:20259-20262.
25. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267:7402-7405.
26. Fan R., Li X., Gu X., Chan J.C., Xu G. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes. Metab. 2010, 12:815-824.
27. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143:4397-4408.
28. 2-terminal kinase pathway. Diabetes 2008, 57:1205-1215.
29. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998, 101:515-520.
30. Fridolf T., Ahrén B. GLP-1 (7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. Diabetes Res. 1991, 16:185-191.
31. Furman B., Ong W.K., Pyne N.J. Cyclic AMP signaling in pancreatic islets. Adv. Exp. Med. Biol. 2010, 654:281-304.
32. Gedulin B.R., Smith P., Prickett K.S., Tryon M., Barnhill S., Reynolds J., Nielsen L.L., Parkes D.G., Young A.A. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005, 48:1380-1385.
33. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993, 268:19650-19655.
34. Greig N.H., Holloway H.W., DeOre K.A., Jani D., Wang Y., Zhou J., Garant M.J., Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
35. Gromada J., Ding W.G., Barg S., Renström E., Rorsman P. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch. 1997, 434:515-524.
36. Gutniak M., Orskov C., Holst J.J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992, 326:1316-1322.
37. Holst J.J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 2009, 297:127-136.
38. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., Göke R., Göke B., Thole H., Zimmermann B., Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995, 58:149-156.
39. Juang J.H., Kuo C.H., Wu C.H., Juang C. Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets. Cell Transplant. 2008, 17:641-647.
40. Kawasaki Y., Harashima S., Sasaki M., Mukai E., Nakamura Y., Harada N., Toyoda K., Hamasaki A., Yamane S., Yamada C., Yamada Y., Seino Y., Inagaki N. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation. Horm. Metab. Res. 2010, 42:311-317.
41. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
42. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care Jun 2007, 30(6):1487-1493.
43. Koehler J.A., Baggio L.L., Lamont B.J., Ali S., Drucker D.J. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009, 58:2148-2161.
44. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., Taylor K., Kim D., Aisporna M., Wang Y., Baron A.D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88:3082-3089.
45. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., Tarui S. Glucagonostatic and insulinotropic action of glucagon like peptide I-(7-36)-amide. Diabetes 1989, 38:902-905.
46. Kwon D.Y., Kim Y.S., Ahn I.S., Kim da S., Kang S., Hong S.M., Park S. Exendin-4 potentiates insulinotropic action partly via increasing β-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J. Pharmacol. Sci. 2009, 111:361-371.
47. La Barre J., Still E.U. Studies on the physiology of secretin. Am. J. Physiol. 1930, 91:649-653.
48. Larsen J., Hylleberg B., Ng K., Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24:1416-1421.
49. Linnebjerg H., Park S., Kothare P.A., Trautmann M.E., Mace K., Fineman M., Wilding I., Nauck M., Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 2008, 151:123-129.
50. Mack C.M., Moore C.X., Jodka C.M., Bhavsar S., Wilson J.K., Hoyt J.A., Roan J.L., Vu C., Laugero K.D., Parkes D.G., Young A.A. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int. J. Obes. (Lond) 2006, 30:1332-1340.
51. Maida A., Hansotia T., Longuet C., Seino Y., Drucker D.J. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for β-cell survival in mice. Gastroenterology 2009, 137:2146-2157.
52. Mann R.J., Nasr N.E., Sinfield J.K., Paci E., Donnelly D. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br. J. Pharmacol. 2010, 160:1973-1984.
53. McIntyre N., Holdsworth C.D., Turner D.S. Intestinal factors in the control of insulin secretion. J. Clin. Endocrinol. Metab. 1965, 25:1317-1324.
54. Meneilly G.S., Greig N., Tildesley H., Habener J.F., Egan J.M., Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003, 26:2835-2841.
55. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214:829-835.
56. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79:616-619.
57. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. 1997, 272:21201-21206.
58. Moretto T.J., Milton D.R., Ridge T.D., Macconell L.A., Okerson T., Wolka A.M., Brodows R.G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2008, 30:1448-1460.
59. Nachnani J.S., Bulchandani D.G., Nookala A., Herndon B., Molteni A., Pandya P., Taylor R., Quinn T., Weide L., Alba L.M. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010, 53:153-159.
60. Natalicchio A., De Stefano F., Orlando M.R., Melchiorre M., Leonardini A., Cignarelli A., Labarbuta R., Marchetti P., Perrini S., Laviola L., Giorgino F. Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-α (TNFα) and inhibits TNFα-induced apoptosis in insulin-secreting cells. Endocrinology 2010, 151:2019-2029.
61. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 91:301-307.
62. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
63. Nauck M.A., Wollschläger D., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
64. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273:E981-E988.
65. Orskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123:2009-2013.
66. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
67. Pérez-Arana G., Blandino-Rosano M., Prada-Oliveira A., Aguilar-Diosdado M., Segundo C. Decrease in β-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of exendin-4. Endocrinology 2010, 151:2538-2546.
68. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
69. Preumont V., Hermans M.P., Brichard S., Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab. 2010, 36:293-298.
70. Primeaux S.D., Barnes M.J., Braymer H.D., Bray G.A. Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats. Int. J. Obes. (Lond) 2010, 34:1427-1433.
71. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40:205-211.
72. Raufman J.P., Jensen R.T., Sutliff V.E., Pisano J.J., Gardner J.D. Actions of Gila monster venom on dispersed acini from guinea pig pancreas. Am. J. Physiol. 1982, 242:G470-G474.
73. Raufman J.P., Singh L., Eng J. Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J. Biol. Chem. 1991, 266:2897-2902.
74. Raufman J.P., Singh L., Singh G., Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J. Biol. Chem. 1992, 267:21432-21437.
75. Raufman J.P. Bioactive peptides from lizard venoms. Regul. Pept. 1996, 16(61):1-18.
76. Reidelberger R.D., Haver A.C., Apenteng B.A., Anders K.L., Steenson S.M. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2010, Jun 17. [Epub ahead of print].
77. Reiner T., Kohler R.H., Liew C.W., Hill J.A., Gaglia J., Kulkarni R.N., Weissleder R. Near-infrared fluorescent probe for imaging of pancreatic beta cells. Bioconjug. Chem. 2010, 21:1362-1368.
78. Runge S., Schimmer S., Oschmann J., Schiødt C.B., Knudsen S.M., Jeppesen C.B., Madsen K., Lau J., Thøgersen H., Rudolph R. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 2007, 46:5830-5840.
79. Schmidt W.E., Siegel E.G., Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985, 28:704-707.
80. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. Sep 2007, 293:R983-R987.
81. Silvestre R.A., Rodríguez-Gallardo J., Egido E.M., Marco J. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur. J. Pharmacol. 2003, 469:195-200.
82. Song W.J., Schreiber W.E., Zhong E., Liu F.F., Kornfeld B.D., Wondisford F.E., Hussain M.A. Exendin-4 stimulation of cyclin A2 in β-cell proliferation. Diabetes 2008, 57:2371-2381.
83. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., Egan J.M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.
84. Suzuki S., Kawai K., Ohashi S., Mukai H., Yamashita K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 1989, 125:3109-3114.
85. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
86. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
87. Tatarkiewicz K., Smith P.A., Sablan E.J., Polizzi C.J., Aumann D.E., Villescaz C., Hargrove D.M., Gedulin B.R., Lu M.G., Adams L., Whisenant T., Roy D., Parkes D.G. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am. J. Physiol. Endocrinol. Metab. Dec 2010, 299:E1076-E1086.
88. Tews D., Lehr S., Hartwig S., Osmers A., Paslack W., Eckel J. Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm. Metab. Res. 2009, 41:294-301.
89. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
90. Thum A., Hupe-Sodmann K., Göke R., Voigt K., Göke B., McGregor G.P. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp. Clin. Endocrinol. Diabetes 2002, 110:113-118.
91. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.
92. Tschen S.I., Dhawan S., Gurlo T., Bhushan A. Age-dependent decline in β-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 2009, 58:1312-1320.
93. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
94. Utaisincharoen P., Mackessy S.P., Miller R.A., Tu A.T. Complete primary structure and biochemical properties of gilatoxin, a serine protease with kallikrein-like and angiotensin-degrading activities. J. Biol. Chem. 1993, 268:21975-21983.
95. van Dieren S., Beulens J.W., van der Schouw Y.T., Grobbee D.E., Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil. 2010, S3-S8. Suppl. 1.
96. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002, 45:1111-1119.
97. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat. J. Clin. Invest. 1995, 95:417-421.
98. Wang Q., Li L., Xu E., Wong V., Rhodes C., Brubaker P.L. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 β-cells. Diabetologia 2004, 47:478-487.
99. Wang L.X., Wang Y.P., Chen Z., Liu X.Y., Liu X.H., Liu L., Chen W.J., Liu L.B. Exendin-4 protects murine pancreatic β-cells from dexamethasone-induced apoptosis through PKA and PI-3K signaling. Diabetes Res. Clin. Pract. 2010, 90:297-304.
100. Washington M.C., Raboin S.J., Thompson W., Larsen C.J., Sayegh A.I. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res. 2010, 1344:124-133.
101. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38:665-673.
102. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
103. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996, 81:327-332.
104. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
105. Xue S., Wasserfall C., Parker M., McGrail S., McGrail K., Campbell-Thompson M., Schatz D.A., Atkinson M.A., Haller M.J. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. J. Diabetes Complicat. 2010, 24:163-167.
106. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
107. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.